Allison Inserro

Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.

She has an MPA from New York University. You can connect with Allison on LinkedIn.

Articles by Allison Inserro

Over 14,600 comments poured into CMS to meet a deadline to comment about proposed changes to its 2019 physician fee schedule for Medicare, with many physician organizations and individuals asking the agency to halt or slow down its plans to cut physician reimbursement for evaluation and management services. While some groups cheered some of the changes—such as broader coverage for telehealth and other digital monitoring—most expressed many concerns.

A new study found no differences in long-term outcomes associated with 2 different approaches to administering trastuzumab (Herceptin) with neoadjuvant chemotherapy in patients with HER2-positive breast cancer. Receiving the combination sequentially rather than concurrently eliminates the known cardiac toxicities associated when chemotherapy and HER2 therapy are given at the same time, researchers said.

A hearing in a federal court in Fort Worth, Texas regarding the Affordable Care Act (ACA) ended Wednesday, with the attorney general for the Lone Star State leading 19 other like-minded Republican states in trying to convince a judge that a preliminary injunction to put the ACA on hold should be granted. Later, Senate Democrats tied the hearing to the Supreme Court nomination hearing for Judge Brett Kavanaugh, who, if confirmed, will likely have to consider the case, Texas v Azar.

The public, including most Republicans, wants protections for people with pre-existing conditions preserved, finds the latest Kaiser Family Foundation health tracking poll. The poll was released as a federal court case regarding the constitutionality of the Affordable Care Act got underway in Texas and as Brett Kavanaugh began his second day of questioning from senators regarding his nomination to the Supreme Court.

The expansion of Medicaid may mitigate health disparities in cancer diagnosis, according to a recent study that found state variation in reductions in the percentage of uninsured patients aged 18 to 64 years diagnosed with cancer. The researchers said that the results have implications for future disparities in state mortality rates, because health insurance coverage is linked to the ability to have better treatment and survival after diagnosis.

A chronic health situation may worsen or, more likely, a crisis may happen suddenly with a call in the middle of the night. Millions of Americans then find themselves as a caregiver to a loved one, and as people live longer, as well as farther away from their families, healthcare providers, healthcare systems, policy makers, and employers need to change how they recognize and respond to the growing numbers of caregivers taking care of older adults, experts in the field said.

During a meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), panelists heard from chimeric antigen receptor (CAR) T therapy drug makers, health researchers, and policy makers, and mostly endorsed including patient-reported outcomes (PROs) in its final national coverage analysis decision, expected next year.

Health organizations reacted with dismay at the decision by the Environmental Protection Agency to reverse the Clean Power Plan, which set limits on coal-fired power plants, and replace it with one called the Affordable Clean Energy Rule, which gives more authority to states in an effort to reduce greenhouse gas emissions. A regulatory impact analysis prepared for the rule indicates 1400 excess deaths created per year by the rule.

The first chimeric antigen receptor (CAR) T-cell therapy was approved just a year ago, changing the face of treatment for certain types of leukemias and lymphomas but carrying with it the downsides of toxicity and cost. A year later, scientists from a major cancer center said that they’ve made headway to discovering more about the T-cell signaling patterns and that understanding more about the biological pathways could help design the next generation of CAR-T treatments.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo